PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 1, 2015SHILAP Revista de lepidopterología259 citationsOpen Access

Anticoagulation Drug Therapy: A Review

KHKatherine HarterMLMichael S. LevineSHSean O. Henderson

Structured PICO

P
Population
Patients requiring parenteral or oral anticoagulation presenting to the emergency department
I
Intervention
Anticoagulation therapy (including heparin, warfarin, and novel anticoagulants)

This review summarizes the indications, mechanisms of action, adverse effects, and reversal strategies for various anticoagulants encountered in the emergency department.

Abstract

Historically, most patients who required parenteral anticoagulation received heparin, whereas those patients requiring oral anticoagulation received warfarin. Due to the narrow therapeutic index and need for frequent laboratory monitoring associated with warfarin, there has been a desire to develop newer, more effective anticoagulants. Consequently, in recent years many novel anticoagulants have been developed. The emergency physician may institute anticoagulation therapy in the short term (e.g. heparin) for a patient being admitted, or may start a novel anticoagulation for a patient being discharged. Similarly, a patient on a novel anticoagulant may present to the emergency department due to a hemorrhagic complication. Consequently, the emergency physician should be familiar with the newer and older anticoagulants. This review emphasizes the indication, mechanism of action, adverse effects, and potential reversal strategies for various anticoagulants that the emergency physician will likely encounter.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Harter et al. (2015) studied this question.

synapsesocial.com/papers/69de583f7ed287395e558908https://doi.org/10.5811/westjem.2014.12.22933
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects2008 · 277 citations
  2. 2Blood coagulation2000 · 603 citations
  3. 3Executive Summary2012 · 1,559 citations
  4. 4Risk Factors for Intracranial Hemorrhage in Acute Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator2012 · 314 citations
  5. 5National Estimates of Emergency Department Visits for Hemorrhage-Related Adverse Events From Clopidogrel Plus Aspirin and From Warfarin2010 · 104 citations